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Abstract
The concept of the currently attracted focal therapy is to treat clinical significant cancer with
minimal invasion of health-related functions such as urethra, sphincter, neurovascular
bundle, and bladder neck. The patients' criteria have been decided with pathologic tumor
features characterized according to a combination of cancer core length and Gleason grade
with prostate biopsy. Because the area involved in a single treatment using high-intensity
focused ultrasound (HIFU) is extremely small, only minor temperature changes are
observed outside of the focal zone. HIFU has been considered as an attractive therapeutic
modality for the focal treatment of the prostate with the aim of curing the cancer while
preserving continenceand erectile function. Clinical trials of focal ablation ofprostate cancer
with HIFU have been reported. In our protocol, magnetic resonance imaging (MRI) has
played amajor role in the diagnosis of the spatial location of the significant cancer, treatment
planning, and the evaluation of the treatment efficacy and recurrence after the treatment. In
the chapter in “MR Imaging,”we want to present the role of MRI in the accurate manage-
ment of focal therapywithHIFU for the localized prostate cancer.
Keywords: prostate cancer, focal therapy, magnetic resonance imaging, high-intensity
focused ultrasound
1. Introduction
High-intensity focused ultrasound (HIFU) produces ultrasound waves generated by a spherical
transducer, delivering ultrasonic energy to pinpoint foci millimeters in diameter [1]. The thermal
and mechanical effects of HIFU cause destruction within prostate tissue [2, 3]. Specifically,
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coagulative degeneration quickly develops and is a primary mechanism for decreasing blood
flow [3, 4]. Cavitation, a mechanical effect of HIFU, occurs because of the rapid cycling from
compression to refraction by the ultrasound waves and results in the formation of microbubbles
in tissue. When these bubbles reach the size of resonance, they collapse and produce high-
pressure shock waves, destroying adjacent tissue [5]. Clinically, HIFU energy is delivered in a
pulsed mode, and pulses are defined by treatment cycles and energy intensity in watts. Pulse
characteristics define the size of the ablation area, including necessary margins to ensure full
tumor coverage. The resulting tissue effects are a function of the frequency (wavelength) and
intensity (I, inW/cm2) of the applied energy. Intensity is a function of the excitation (voltage) and
duration of the energy pulse. The exact size of the ablated area depends on the type of device
used, shape of the piezoceramic working element of the transducer, ultrasound frequency and
duration of pulsed energy applied, degree of sonication absorption by the tumor tissue, and focal
intensity achieved.
Because the area involved in a single treatment using HIFU is extremely small, only minor
temperature changes are observed outside of the focal zone [3], making it an attractive thera-
peutic modality for focal treatment of the prostate, with the aim of curing the cancer while
preserving continence and erectile function. Clinical trials of focal ablation of prostate cancers
with HIFU have been reported [6–11]. In the management of the focal therapy, MRI has the
role in the localization of the targeted lesion, the evaluation of the treatment effectiveness, and
the local recurrence after the treatment.
2. The technology of the HIFU in the treatment of the prostate cancer
After the early studies for the treatment of organ-confined prostate cancer, the Sonablate®
device and Ablatherm® device have been further enhanced to include treatment planning
capabilities and improved therapeutic technologies.
In the treatment planning, the Sonablate® transrectal HIFU probes use proprietary transducer
technology with low-energy ultrasound (4 MHz) for imaging of the prostate and high-energy
ablative pulses (site intensity: 1300–2200 W/cm2) for treatment delivery. For the Ablatherm®
device, the transrectal HIFU probes use 7.5 MHz pulses for imaging of the prostate and 3 MHz
for the delivery of high-energy ablative pulses (site intensity, 1300–2200 W/cm2). In recent
applications of HIFU, the treatment range was planned using a MRI-TRUS fusion image.
Additionally, reconstructed three-dimensional (3D) planning modes have been integrated into
the SB 500 V4 and AB integrated devices, facilitating accurate planning of treatment range.
Because of the inherent technology of HIFU treatments, there is no need to puncture the
prostate during treatment; however, this makes accurate treatment planning essential for
successful focal HIFU therapy.
In the treatment, intraoperative images are available during the procedure. The “popcorn”
phenomena formed by the cavitations of tissue may act as an indicator of treatment efficacy.
The SB500 tissue change monitoring system (TCM) predicts treatment efficacy by calculation
of radio frequency signal from an area of interest and classifies it based on a 3-color system;
green: insufficient change to cure, yellow: moderate change, and orange: large change. Based
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on the color indicated on the treated area, intraoperative retreatment for an insufficiently
treated zone (green area) would then be performed. A recent development in the field of
adaptive treatment planning is the Focal One®. This device has a dynamic focusing transducer
made of 16 isocentric rings and allows the user to electronically steer the ultrasound beam and
move the focal point of the transducer to a maximum of eight different points (32–67 mm from
the transducer).
3. The role of MRI in the management of focal therapy
3.1. The localization of the clinically significant cancer in the prostate with MRI-TRUS
fusion image-guided prostate biopsy
Multiparametric MRI (mpMRI) improves the imaging of the clinically significant prostate cancer
in the prostate [12, 13], and the information of mpMRI has been used for the precise diagnosis
and localization of the clinically significant prostate cancer. MRI-TRUS fusion image-guided
biopsy achieved accurate prostate biopsy based on MRI, combining the superior sensitivity of
MRI for targeting cancer-suspicious lesions with the practicality and familiarity of TRUS. With
the MRI-TRUS fusion devices, the stored MRI and real-time TRUS are superimposed using
computer software to enable targeted biopsy of cancer-suspicious lesions [14]. MRI-TRUS fusion
biopsy device “BioJet®” was approved by FDA after the evaluation of the accuracy with phan-
toms. We reported the BioJet® experience of the usefulness of the precise diagnosis of the
clinically significant cancer [15]. In the 30 patients from whom whole-mount specimens were
taken, we found 43 clinically significant cancers, of which 41 (95%) had been detected by both the
targeted and systematic biopsies. The median major diameter of significant cancers in the whole-
gland specimens was 12 (range: 5–28) mm; lesions ≤10 mm represented 59% of the significant
cancers (n = 24). Of the significant cancers ≤10 mm (n = 24) in whole-mount specimens, 96%
(n = 23) were correctly diagnosed by biopsy. Gleason scores and locations of biopsy-proven
significant cancers corresponded to histopathological findings for the whole-mount specimens,
since the localization of the clinically significant cancer in the prostate is important for the precise
focal therapy. Since February 2016, the biopsy with BioJet was approved as the advance medical
technique by Japanese Ministry of Health, Labor, and Welfare.
3.2. The evaluation of the effectiveness and the local recurrence of the prostate cancer
after the focal therapy with HIFU
The treated areas with HIFU in the prostate appear as nonenhanced areas on contrast-
enhanced T1-weighted MRI, and subsequent transrectal biopsies have been able to remove
homogenous necrotic tissue sections from the nonenhanced area [16]. Therefore, contrast-
enhanced MRI has been considered to be the evaluation method of choice to demonstrate the
effectiveness of HIFU for localized prostate cancer. We reported the time-dependent changes in
blood flow within the prostate treated with HIFU on contrast-enhanced MRI between postop-
erative days 1 and 14 [16]. In addition, pathological analysis showed vessel damage with
coagulative degeneration and detachment of vascular endothelial cells in HIFU-treated pros-
tate tissue [16]. Previous studies [5] have shown that these time-dependent changes in blood
flow within the prostate are likely due to the primary thermal effects induced on the tissue and
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vessel damage by coagulative degeneration in the prostate and that cavitation rapidly induces
the detachment of vascular endothelial cells, gradually decreasing blood flow secondary to
vessel obstruction. Future large-scale studies should investigate the most appropriate timing of
contrast-enhanced MRI for precise feedback regarding the effectiveness of HIFU. Using the
contrast-enhanced MRI, the evaluation of the effectiveness and the local recurrence of the
prostate cancer needs to be evaluated after the focal therapy with HIFU.
4. The original protocol and the early experience of the focal therapy for
the prostate cancer in our institution
Since 2016, the patients with low- and intermediate-risk group who were diagnosed the spatial
localization of the prostate significant cancer in the prostate were recruited prospectively. The
spatial localization of the significant cancer was diagnosed with MRI-transrectal ultrasound
(TRUS) fusion image-guided transperineal prostate biopsy using the BioJet® system (D&K
Technologies GmbH, Barum, Germany). The focal therapy was performed to the significant
cancer detected regions with transrectal HIFU using Sonablate® 500 (SonaCare medical, Indi-
anapolis, IN, USA). To evaluate the efficacy of the treatment, serum prostate-specific antigen
(PSA) kinetics and three-dimensional (3D) reconstructed multiparametric MRI were analyzed
(Figure 1). To evaluate the invasiveness, questionnaires (IPSS, QOL, OABSS, IIEF-5, SF-36
Japanese version 2) and uroflowmetry were performed. Adverse event was evaluated with
Common Terminology Criteria for Adverse Events (CTCAE) ver.4.0. Fifteen patients with
median age of 64 years (48–79) and median PSA of 7.2 ng/ml (4.67–15.99) were treated. All
men (15 of 15 patients) had pad-free/leak-free continence at 1 and 3 months after the treatment.
The proportion of men with erections sufficient for penetration was not changed from 73%
(11 of 15 patients) to 73%. Catheterization was within 24 hours after the treatment in all
patients. The median PSA of the patients significantly dropped from 7.2 to 1.76 ng/ml
(p = 0.001) at 3 months after the treatment. The contrast-enhanced MRI and dynamic MRI
showed the disappearance of blood flow in all targeted regions of the prostate with 3D
evaluation of the MRI. There was no significant difference between before and after the
treatment at 3 months in urinary symptoms (IPSS change, p = 0.3, QOL change p = 0.7, OABSS
change, p = 0.6, max flow rate change, p = 0.6, residual urine change, p = 0.1), erectile function
(IIEF-5 change, p = 0.6), and QOL (SF-36 change in all domains). Urinary tract infection with
Figure 1. The protocol schema of focal HIFU treatment for the prostate cancer in our institution.
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CTCAE Grade 2 was found in one patient (6.7%). In conclusion, the anatomical region selected
focal therapy with HIFU would have potential to provide promising results with accurate
treatment for the significant cancer and low morbidity.
5. Conclusion
MRI has the role of the management of the focal therapy with HIFU. Clinical trials have shown
potential for effective focal treatment with HIFU-localized prostate cancer. Further oncological
and functional outcomes in the patients treatedwith focal therapywith HIFUwould be expected.
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